A research team co-led by scientists at the University of Arizona College of Medicine – Tucson found that an osteoporosis drug might counter a rare genetic mutation underlying a type of heart disease.

Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA ...

Pharmaceuticals announced the NMPA, National Medical Products Administration, approval of Cumberland’s Vibativ injection in ...

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies.

The HALO™ Clarity is powered by Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS) technology, delivering non-invasive, deep-brain stimulation without the use of drugs or invasive ...

Per Reuters, 20 people who worked in the FDA’s office of neurological and physical medicine devices got axed as part of a ...

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir?the company's twice-yearly injectable HIV ...

Innovative lipid nanoparticles enable mRNA delivery to the brain, offering new avenues for treating neurological disorders by crossing the blood-brain barrier.

The drug, which is currently approved as Sunlenca for multi-drug resistant HIV, would be the first twice-yearly PrEP option on the market. The company’s FDA bid is the first step of its detailed ...

Today we’re talking about bird flu. It’s infecting flocks of chickens, causing egg prices to rise across the country, plus herds of dairy cattle and people are getting sick to ...

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

I'm Ryan Weispfenning, vice president and head of Medtronic investor relations, and I appreciate that you're joining us for our fiscal '25 third-quarter video earnings webcast. Before we go inside to ...